MCID: DBT005
MIFTS: 54

Diabetes Insipidus

Categories: Endocrine diseases, Rare diseases, Neuronal diseases, Nephrological diseases

Aliases & Classifications for Diabetes Insipidus

MalaCards integrated aliases for Diabetes Insipidus:

Name: Diabetes Insipidus 12 72 28 40 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9409
ICD10 32 E23.2
ICD9CM 34 253.5
MeSH 41 D003919
NCIt 46 C43263
SNOMED-CT 64 15771004 190484000
UMLS 69 C0011848

Summaries for Diabetes Insipidus

MedlinePlus : 40 Diabetes insipidus (DI) causes frequent urination. You become extremely thirsty, so you drink. Then you urinate. This cycle can keep you from sleeping or even make you wet the bed. Your body produces lots of urine that is almost all water. DI is different from diabetes mellitus (DM), which involves insulin problems and high blood sugar. The symptoms can be similar. However, DI is related to how your kidneys handle fluids. It's much less common than DM. Urine and blood tests can show which one you have. Usually, DI is caused by a problem with your pituitary gland or your kidneys. Treatment depends on the cause of the problem. Medicines can often help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Insipidus is related to diabetes insipidus, nephrogenic, x-linked and diabetes insipidus, nephrogenic, autosomal. An important gene associated with Diabetes Insipidus is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroscience and Glucose / Energy Metabolism. The drugs Norepinephrine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include heart, kidney and pituitary, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 72 Diabetes insipidus (DI) is a condition characterized by large amounts of dilute urine and increased... more...

Related Diseases for Diabetes Insipidus

Diseases in the Diabetes Insipidus family:

Hereditary Central Diabetes Insipidus Acquired Central Diabetes Insipidus

Diseases related to Diabetes Insipidus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
# Related Disease Score Top Affiliating Genes
1 diabetes insipidus, nephrogenic, x-linked 34.7 AQP2 AVPR2
2 diabetes insipidus, nephrogenic, autosomal 33.7 AQP2 ARHGAP4 AVP AVPR2 CLCNKA SLC12A1
3 wolfram syndrome 1 33.6 AVP WFS1
4 wolfram syndrome 33.5 AVP CISD2 WFS1
5 diabetes insipidus, neurohypophyseal 33.0 AQP2 AVP AVPR2 POMC PRL WFS1
6 wolfram syndrome 2 32.3 CISD2 WFS1
7 nephrogenic syndrome of inappropriate antidiuresis 30.2 AVP AVPR2
8 pituitary hormone deficiency, combined, 2 30.0 AVP POMC PRL
9 syndrome of inappropriate antidiuretic hormone 30.0 AQP2 AVP AVPR2 POMC
10 burns 29.9 CRH INS
11 hypoadrenalism 29.7 CRH POMC
12 hypoaldosteronism 29.6 POMC REN
13 bartter disease 29.5 CLCNKA REN SLC12A1
14 pituitary apoplexy 29.4 INS POMC PRL
15 antenatal bartter syndrome 29.4 REN SLC12A1
16 conn's syndrome 29.2 CRH POMC REN
17 pituitary infarct 29.2 POMC PRL
18 adenohypophysitis 29.2 POMC PRL
19 amenorrhea 29.2 CRH POMC PRL
20 hypopituitarism 29.2 CRH INS POMC PRL
21 empty sella syndrome 29.1 INS POMC PRL
22 hypokalemia 28.9 AQP2 POMC REN SLC12A1
23 acromegaly 28.9 INS POMC PRL
24 bulimia nervosa 2 28.6 CRH POMC PRL
25 chromophobe adenoma 28.6 AVP INS POMC PRL
26 sheehan syndrome 28.3 CRH INS POMC PRL
27 diabetes insipidus, nephrogenic, with mental retardation and intracerebral calcification 12.3
28 hereditary central diabetes insipidus 12.3
29 acquired central diabetes insipidus 12.3
30 gestational diabetes insipidus 12.3
31 dipsogenic diabetes insipidus 12.2
32 hypopituitarism, congenital, with central diabetes insipidus 12.0
33 x-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome 12.0
34 langerhans cell histiocytosis 11.4
35 wolfram syndrome, mitochondrial form 11.0
36 hyperostosis frontalis interna 11.0
37 polyhydramnios, megalencephaly, and symptomatic epilepsy 11.0
38 wolfram-like syndrome, autosomal dominant 11.0
39 culler-jones syndrome 11.0
40 hashimoto-pritzker syndrome 11.0
41 bronchus cancer 10.5 AVP AVPR2
42 seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance 10.4 AQP2 AVP
43 peripheral vertigo 10.4 AQP2 AVP
44 benign essential hypertension 10.4 AVP REN
45 histiocytosis 10.3
46 vestibular disease 10.3 AQP2 AVP
47 secondary adrenal insufficiency 10.3 AVP INS
48 diabetes mellitus 10.3
49 blood group, i system 10.3
50 leukemia 10.3

Comorbidity relations with Diabetes Insipidus via Phenotypic Disease Network (PDN):


Acute Cystitis Diabetes Insipidus, Nephrogenic, Autosomal
Hypothyroidism Pituitary Hormone Deficiency, Combined, 2

Graphical network of the top 20 diseases related to Diabetes Insipidus:



Diseases related to Diabetes Insipidus

Symptoms & Phenotypes for Diabetes Insipidus

MGI Mouse Phenotypes related to Diabetes Insipidus:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 WFS1 CRH INS POMC AQP2 PRL
2 growth/size/body region MP:0005378 9.91 SLC12A1 CISD2 WFS1 CRH INS POMC
3 homeostasis/metabolism MP:0005376 9.9 CISD2 WFS1 CRH INS POMC AQP2
4 integument MP:0010771 9.61 CISD2 WFS1 CRH INS POMC AQP2
5 renal/urinary system MP:0005367 9.28 CRH INS POMC AQP2 AVP REN

Drugs & Therapeutics for Diabetes Insipidus

Drugs for Diabetes Insipidus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
2
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 51-43-4 5816
3
Furosemide Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 54-31-9 3440
4
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-23-7 657311 5754
5
Conivaptan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 210101-16-9 151171
6
Tolvaptan Approved Phase 4,Phase 3,Phase 2,Phase 1 150683-30-0 216237
7 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1 329-65-7
8
Misoprostol Approved Phase 4 59122-46-2 5282381
9
Phenylephrine Approved Phase 4,Phase 2 59-42-7 6041
10
Oxymetazoline Approved, Investigational Phase 4,Phase 2 1491-59-4 4636
11
Ephedrine Approved Phase 4,Phase 2 299-42-3 9294
12
Angiotensin II Approved, Investigational Phase 4,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
14
Benzocaine Approved, Investigational Phase 4,Phase 2 1994-09-7, 94-09-7 2337
15
Pseudoephedrine Approved Phase 4,Phase 2 90-82-4 7028
16
Chlorothiazide Approved, Vet_approved Phase 4 58-94-6 2720
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
18
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
19
Metolazone Approved Phase 4,Phase 1 17560-51-9 4170
20 tannic acid Approved, Nutraceutical Phase 4,Phase 2
21
Butyric Acid Experimental, Investigational Phase 4,Phase 3 107-92-6 264
22
Synephrine Experimental Phase 4 1994-07-5, 94-07-5 7172
23 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
24 diuretics Phase 4,Phase 2,Phase 3,Phase 1
25 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1
27 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1
29 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1
30 Mydriatics Phase 4,Phase 3,Phase 2,Phase 1
31 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2,Phase 1
32 Sodium Potassium Chloride Symporter Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
33 Natriuretic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Coagulants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Cortisol succinate Phase 4,Phase 2,Phase 3
37 Hemostatics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
39 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Anesthetics Phase 4,Phase 1
41 Vasopressins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Deamino Arginine Vasopressin Phase 4,Phase 3,Phase 2,Phase 1
43 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Oxytocics Phase 4,Phase 2,Phase 1,Early Phase 1
45 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2,Phase 3
50 Hydrocortisone acetate Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 398)

# Name Status NCT ID Phase Drugs
1 Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population Unknown status NCT02584231 Phase 4 desmopressin
2 Desmopressin for Improving Nocturnal Enuresis in Patients After Radical Cystectomy With Bladder Reconstruction Unknown status NCT01582542 Phase 4 Desmopressin
3 Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study Unknown status NCT01439997 Phase 4 Desmopressin
4 Desmopressin for Bleeding Related to Low Body Temperature Unknown status NCT00902057 Phase 4 desmopressin;desmopressin;desmopressin;placebo
5 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
6 Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites Unknown status NCT01552590 Phase 4 Tolvaptan;Placebo
7 Pilot Study of Using Copeptin to Predict Response to Tolvaptan Completed NCT01346072 Phase 4 tolvaptan
8 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy Completed NCT00748072 Phase 4 DDAVP;saline solution
9 Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest Completed NCT00127907 Phase 4 epinephrine (1 mg/1 mL);arginine-vasopressin (40 UI/2 mL)
10 Desmopressin in Cardiac Surgery Completed NCT00337766 Phase 4 Desmopressin (DDAVP);Placebo
11 Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity Completed NCT00902655 Phase 4 Desmopressin
12 Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy Completed NCT01700478 Phase 4 Misoprostol + vasopressin;Vasopressin
13 Desmopressin Melt: Impact on Sleep and Daytime Functioning Completed NCT01645475 Phase 4 Desmopressin lyophilisate (Melt)
14 Effects of Tolvaptan in Healthy Adults Completed NCT01973140 Phase 4 Tolvaptan;Hypertonic saline infusion
15 Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients Completed NCT01752543 Phase 4 Conivaptan;Placebo (Dextrose)
16 Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery Completed NCT02125188 Phase 4 Desmopressin;saline
17 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4 desmopressin
18 Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study Completed NCT01435083 Phase 4 Desmopressin
19 Influence of Food-intake on Desmopressin Oral Tablets and MELT-formulation Completed NCT01036841 Phase 4 desmopressin tablet;desmopressin MELT formulation
20 A Study of Oral Desmopressin in Previously Untreated Children Aged 5 to 15 Years With Primary Nocturnal Enuresis Completed NCT00245479 Phase 4 Primary nocturnal enuresis
21 A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE) Completed NCT00209261 Phase 4 MINIRIN Oral Lyophilisate;Minirin tablet
22 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
23 Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial Completed NCT00799292 Phase 4 Vasopressin
24 Effects of Vasopressors on Immune Response Completed NCT02675868 Phase 4 Norepinephrine;Phenylephrine;Vasopressins;Placebo
25 Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients Completed NCT01439009 Phase 4 Tolvaptan;Placebo of tolvaptan
26 Tolvaptan for Ascites in Cirrhotic Patients Completed NCT01292304 Phase 4 Tolvaptan
27 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4 Tolvaptan;Placebo
28 A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia Completed NCT00435591 Phase 4 Conivaptan;placebo
29 Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure Completed NCT01863511 Phase 4 loop diuretic;tolvaptan
30 The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement Completed NCT02644616 Phase 4 tolvaptan+torasemide;placebo+torasemide
31 Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders Recruiting NCT02476409 Phase 4 tolvaptan
32 The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings. Recruiting NCT03389412 Phase 4 Desmopressin
33 Exercise Versus DDAVP in Patients With Mild Hemophilia A Recruiting NCT03379974 Phase 4 DDAVP Inhalant Product
34 DDAVP vs. Exercise in Patients With Mild Hemophilia A Recruiting NCT03136003 Phase 4 DDAVP
35 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
36 Regional Tolvaptan Registry Recruiting NCT02666651 Phase 4 Tolvaptan
37 Tolvaptan for Advanced or Refractory Heart Failure Recruiting NCT02959411 Phase 4 Tolvaptan;Standard of care diuretic therapy
38 Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest Recruiting NCT03317197 Phase 4 Control Group;Experimental Group 1;Experimental Group 2;Experimental Group 3
39 Vasoactive Drugs in Intensive Care Unit Recruiting NCT02118467 Phase 4 Norepinephrine;Epinephrine;Phenylephrine;Vasopressin
40 Aquaresis Utility for Hyponatremic Acute Heart Failure Study Recruiting NCT02183792 Phase 4 Tolvaptan;Furosemide
41 Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery Active, not recruiting NCT03343418 Phase 4 Desmopressin;Placebo
42 Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure Enrolling by invitation NCT02606253 Phase 4 tolvaptan;Chlorothiazide;Metolazone
43 Vasoactive Hormones and Oxygen Saturation During Apneic Events in Patients With Obstructive Sleep Apnea Suspended NCT00438412 Phase 4
44 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
45 Desmopressin as Treatment for Postoperative Bleeding After Cardiac Surgery Terminated NCT00885924 Phase 4 Desmopressin;Placebo
46 Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson Disease Terminated NCT00806468 Phase 4 Desmotabs
47 Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure Terminated NCT02352285 Phase 4 Tolvaptan;Placebo
48 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
49 Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine Withdrawn NCT00298753 Phase 4
50 Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion Withdrawn NCT00806910 Phase 4 Conivaptan

Search NIH Clinical Center for Diabetes Insipidus

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: diabetes insipidus

Genetic Tests for Diabetes Insipidus

Genetic tests related to Diabetes Insipidus:

# Genetic test Affiliating Genes
1 Diabetes Insipidus 28

Anatomical Context for Diabetes Insipidus

MalaCards organs/tissues related to Diabetes Insipidus:

38
Heart, Kidney, Pituitary, Liver, Testes, Brain, Lung

Publications for Diabetes Insipidus

Articles related to Diabetes Insipidus:

(show top 50) (show all 1290)
# Title Authors Year
1
'If there were water we should stop and drink': neurofibromatosis presenting with diabetes insipidus. ( 29440241 )
2018
2
Contiguous 22.1-kb deletion embracing AVPR2 and ARHGAP4 genes at novel breakpoints leads to nephrogenic diabetes insipidus in a Chinese pedigree. ( 29394883 )
2018
3
The clinical course and pathophysiological investigation of adolescent gestational diabetes insipidus: a case report. ( 29378555 )
2018
4
Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas. ( 29395172 )
2018
5
Rapid differential diagnosis of diabetes insipidus in a 7-month-old infant: The copeptin approach. ( 29241593 )
2018
6
Delayed Occurrence of Diabetes Insipidus After Transsphenoidal Surgery with Radiologic Evaluation of the Pituitary Stalk on Magnetic Resonance Imaging. ( 29229338 )
2018
7
Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. ( 29081004 )
2018
8
Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. ( 29220526 )
2018
9
Functional characterization of AVPR2 mutants found in Turkish patients with nephrogenic diabetes insipidus. ( 29117938 )
2018
10
Tamoxifen attenuates development of lithium-induced nephrogenic diabetes insipidus in rats. ( 29357422 )
2018
11
Relation between change in treatment for central diabetes insipidus and body weight loss. ( 29424204 )
2018
12
Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. ( 29141992 )
2018
13
Pitfall in the Diagnosis of Diabetes Insipidus and Pregnancy. ( 28819576 )
2017
14
Value of Renal Biopsy in Diagnosing Infantile Nephropathic Cystinosis Associated With Secondary Nephrogenic Diabetes Insipidus. ( 28276300 )
2017
15
Tuberculoma of the pituitary gland presenting as diabetes insipidus. ( 28681785 )
2017
16
Xanthomatous Hypophysitis Presenting with Diabetes Insipidus Completely Cured Through Transsphenoidal Surgery: Case Report and Literature Review. ( 28583458 )
2017
17
Oral administration of diluted nasal desmopressin in managing neonatal central diabetes insipidus. ( 28599389 )
2017
18
Transient Central Diabetes Insipidus and Marked Hypernatremia following Cardiorespiratory Arrest. ( 28758038 )
2017
19
Amyloid-like aggregation of provasopressin in diabetes insipidus and secretory granule sorting. ( 28122547 )
2017
20
Xanthoma Disseminatum in a Young Patient with Diabetes Insipidus. ( 28523884 )
2017
21
Congenital nephrogenic diabetes insipidus complicated with Hinman syndrome. ( 28504419 )
2017
22
Mice deficient for ERAD machinery component Sel1L develop central diabetes insipidus. ( 28920918 )
2017
23
A case of gestational central diabetes insipidus with oligohydramnios. ( 28764595 )
2017
24
Adipsic diabetes insipidus in adult patients. ( 28074401 )
2017
25
Treatment regimens by pediatric nephrologists in children with congenital nephrogenic diabetes insipidus: A MWPNC studya8c. ( 29162216 )
2017
26
Factors Associated with Postoperative Diabetes Insipidus after Pituitary Surgery. ( 29199401 )
2017
27
Transient Diabetes Insipidus Following Thermal Burn; A Case Report and Literature Review. ( 29177181 )
2017
28
Recovery from diabetes insipidus and preservation of thyroid function after craniopharyngioma removal and pituitary stalk sectioning. ( 28917091 )
2017
29
Novel<i>de novo AVPR2</i>Variant in a Patient with Congenital Nephrogenic Diabetes Insipidus. ( 29177155 )
2017
30
A novel SLC12A1 gene mutation associated with hyperparathyroidism, hypercalcemia, nephrogenic diabetes insipidus, and nephrocalcinosis in four patients. ( 28095294 )
2017
31
A Case of Multiple Myeloma Presenting with Diabetes Insipidus. ( 28690897 )
2017
32
Effect of Preserving the Pituitary Stalk During Resection of Craniopharyngioma in Children on the Diabetes Insipidus and Relapse Rates and Long-Term Outcomes. ( 28749844 )
2017
33
Two Cases of Central Diabetes Insipidus in Refractory Antineutrophil Cytoplasmic Antibody-associated Vasculitis. ( 28943556 )
2017
34
Transient Diabetes Insipidus After Discontinuation of Vasopressin in Neurological Intensive Care Unit Patients: Case Series and Literature Review. ( 27742514 )
2017
35
Incidence of Diabetes Insipidus in Postoperative Period among the Patients Undergoing Pituitary Tumour Surgery. ( 28919622 )
2017
36
Diabetes insipidus and hypopituitarism in HIV: an unexpected cause. ( 28620498 )
2017
37
Overlap of Post-obstructive Diuresis and Unmasked Diabetes Insipidus in a Case of IgG4-related Retroperitoneal Fibrosis and Tuberoinfundibular Hypophysitis: A Case Report and Review of the Literature. ( 28049999 )
2017
38
Diabetes insipidus and the use of desmopressin in hospitalised children. ( 28073809 )
2017
39
Central Diabetes Insipidus and Hyperglycemic Hyperosmolar State Following Accidental Carbon Monoxide Poisoning. ( 28690939 )
2017
40
Opioid-induced hyponatremia in a patient with central diabetes insipidus: independence from ADH. ( 28593907 )
2017
41
Diabetes Insipidus ( 29262153 )
2017
42
Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update. ( 29125546 )
2017
43
Diabetes insipidus after discontinuation of vasopressin infusion for septic shock. ( 28895166 )
2017
44
The soluble (Pro) renin receptor does not influence lithium-induced diabetes insipidus but does provoke beiging of white adipose tissue in mice. ( 29138356 )
2017
45
A 42-Year-Old Male with Diabetes Insipidus. ( 28805007 )
2017
46
Delirium after thiazide diuretic suspension can unmask diabetes insipidus. ( 29265751 )
2017
47
Congenital nephrogenic diabetes insipidus in the Corpus Hippocraticum: The first description. ( 28742510 )
2017
48
Diabetes insipidus is an unfavorable prognostic factor for response to glucocorticoids in patients with autoimmune hypophysitis. ( 28626085 )
2017
49
A Case of Osteomyelitis of the toe caused by Coccidioidomycosis in a 17 year-old with Diabetes Insipidus. ( 28560172 )
2017
50
A case of myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated hypertrophic pachymeningitis presenting with multiple cranial nerve palsies and diabetes insipidus. ( 27098904 )
2016

Variations for Diabetes Insipidus

Expression for Diabetes Insipidus

Search GEO for disease gene expression data for Diabetes Insipidus.

Pathways for Diabetes Insipidus

GO Terms for Diabetes Insipidus

Cellular components related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 INS PRL

Biological processes related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.71 AVP INS POMC PRL
2 positive regulation of gene expression GO:0010628 9.62 AVP AVPR2 CRH INS
3 response to immobilization stress GO:0035902 9.37 CRH REN
4 glucose homeostasis GO:0042593 9.33 INS POMC WFS1
5 water transport GO:0006833 9.26 AQP2 AVP
6 excretion GO:0007588 9.13 AQP2 AVPR2 CLCNKA
7 renal water homeostasis GO:0003091 8.92 AQP2 AVP AVPR2 WFS1

Molecular functions related to Diabetes Insipidus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.56 AVP CRH POMC REN
2 insulin-like growth factor receptor binding GO:0005159 9.16 INS REN
3 neuropeptide hormone activity GO:0005184 9.13 AVP CRH POMC
4 hormone activity GO:0005179 9.02 AVP CRH INS POMC PRL

Sources for Diabetes Insipidus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....